NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it has licensed Axis-Shield’s early-detection rheumatoid arthritis test.
 
Bio-Rad said the Axis-Shield assay, which is based on anti-CCP antibodies, will run on its BioPlex 2200 system.
 
The BP2200 is an automated multiplexing system that works at a rate of 2,200 results per hour. The platform already holds several assays designed for other autoimmune diseases.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.